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BACKGROUND

PREVENTION

According to the World Health Organization, there
is a daily incidence of over one million sexually
transmitted infections worldwide. Chlamydia and
gonorrhea are the two most common reportable
communicable infections in the United States. The
public health burden is significant. Prevalence has
continued to increase and infection rates are highest
among adolescents and young adults of both sexes.
Often asymptomatic and underdiagnosed, complications including pelvic inflammatory disease puts
women of childbearing age at a higher risk for ectopic pregnancy and infertility. In childbirth, newborns of untreated mothers are at risk for neonatal
chlamydial pneumonia or gonococcal, chlamydial
ophthalmia. Infection in men may lead to urethritis
and epididymitis. Both infections may increase the
risk of HIV transmission.
In 2021, both the United States Preventive Services
Task Force (USPSTF) and the Centers for Disease
Control (CDC) presented updated guidelines for the
screening and management of chlamydial and gonococcal infections.

Who should be screened for chlamydia and gonorrhea infection?
The USPSTF updated their guidelines for gonorrhea
and chlamydia screening in September, 2021 (Table 1).
For all sexually active female patients aged 24
and under, including those who are pregnant, the
USPSTF recommends annual screening for gonorrhea and chlamydia.5 An active discussion of sexual practices should be emphasized during routine
health visits. Women aged 25 and older who are at
increased risk for infection should also be screened.
In men who have sex with men, annual screening for
chlamydia infection is recommended and screening
should be considered for sexually active young men
in settings where the prevalence of chlamydia is high.
Screen patients with chlamydia infection for other sexually transmitted infections such as HIV and
syphilis. Screen patients with other sexually transmitted infections for chlamydia.

Table 1. United States Preventive Services Task Force updated guidelines, September, 2021.
Population

Recommendation

Sexually active women,
including pregnant persons

The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years
or older who are at an increased risk for infection

B

Sexually active women,
including pregnant persons

The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years
or older who are at an increased risk for infection

B

Sexually active men

The USPSTF concludes that the current evidence is insufficient
to assess the balance of benefits and harms of screening for
chlamydia and gonorrhea in men.
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DIAGNOSIS
What presenting symptoms are typical of chlamydia and gonorrhea infections?
Gonorrhea most often presents with urethritis or cervicitis in women and urethritis in men. Symptoms
including mucoid discharge, dysuria, and genital
pain typically appear within 10 days of exposure to
the infected partner.3 Less common presentations
include proctitis, prostatitis and pharyngitis. In men
presenting with rectal pain, consider a diagnosis
of gonococcal proctitis. In one multi-center study,
there was found to be a 10% prevalence of gonococcal proctitis in men who engaged in receptive anal
intercourse with other men. In addition, those with
gonococcal proctitis have a 3-fold increased risk of
transmitting HIV to their partner.4
While sharing several similar characteristics to gonococcal infections, cases of Chlamydia urethritis and
cervicitis are often asymptomatic. In men, scant urethral discharge may be the only presenting symptom.
The onset of symptoms tends to be slower than in
gonococcal infections, up to 14 days after sexual contact with an infected partner. In addition, epididymitis
as evidenced by unilateral testicular pain and swelling
is more commonly seen with chlamydial infections.
What testing modality should be used to test for
chlamydia and gonorrhea?
Utilize nucleic acid amplification tests to confirm infection. NAAT testing can detect C. trachomatis and
N. gonorrhoeae in the same specimen and has both
high sensitivity (chlamydia 96%, gonococcus 97%)
and specificity (chlamydia 99%, gonococcus 100%).
NAAT testing is appropriate for a range of sample
types including urine, endocervical, urethral, and vulvovaginal specimens. However, vaginal specimens are
preferred because urinary samples are less sensitive
and may detect up to 10% fewer infections than vaginal or endocervical swabs. In men, employ a firstcatch urine specimen rather than a urethral swab. Rectal and oropharyngeal swabs may also be performed.
MANAGEMENT
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py have been removed. Oral regimens are less preferred but cefixime may be considered if injectable
ceftriaxone is not available.3
For chlamydia trachomatis, first-line treatment for
suspected or confirmed infections of the cervix, urethra, pharynx and/or rectum is doxycycline 100 mg
orally twice daily for 7 days. In pregnancy or when
non-adherence to therapy is a concern, utilize Azithromycin 1 gram orally in a single dose. Azithromycin is an effective alternative but some studies have
identified higher rates of microbiological treatment
failure as compared to doxycycline (RR 2.45, 95%
CI 1.36 to 4.41) especially when treating men. Less
preferred alternative oral antibiotics include levofloxacin and amoxicillin. The same treatment regimen applies regardless of HIV status. Additional
important counseling includes the testing and treating of sexual partners and avoiding sexual contact
for 7 days after the start of treatment.
Is a test of cure necessary?
No. Repeat testing 4 weeks after completing therapy
is not recommended unless the patient is pregnant,
symptoms persist, or there is concern for reinfection
or non-adherence to the prescribed therapy.
Is screening for reinfection necessary?
Yes. Screening for reinfection (repeat testing 3-4
months after treatment) is recommended for all patients, regardless of whether the sex partners were
also treated. More than 90% of infected individuals
achieve eradication with treatment but reinfection
rates at 1 year are approximately 20%.
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